← Leaderboards
Sanford M Simon
Rockefeller University
$20,890,479
Attributed
$20,890,479
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,268,354 · 16
By mechanism
U54$10,566,625 · 4
R01$9,456,417 · 7
P20$3,195,533 · 1
P50$1,955,529 · 2
R56$593,250 · 1
R21$501,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsCellsAffectVirusMalignant NeoplasmsFibrolamellar Hepatocellular CarcinomaInsightTechnologyCyclic Amp-Dependent Protein KinasesNeoplasm MetastasisPrkaca GeneOperative Surgical ProceduresTumorCatalytic DomainStructureGenomeChimeric ProteinsLiverMalignant Childhood NeoplasmEventKineticsOrganellesPhosphotransferasesAdolescent And Young Adult
Grant awards (53)
Project 1$285,839
P50 · FY2025 · CA · contact PI
Project 1$461,849
P50 · FY2024 · CA · contact PI
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma$403,108
R01 · FY2024 · CA · contact PI
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma$415,837
R01 · FY2023 · CA · contact PI
Targeting the oncoprotein that drives FLC$188,750
U54 · FY2023 · CA · contact PI
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma$188,750
U54 · FY2023 · CA · contact PI
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma$415,837
R01 · FY2022 · CA · contact PI
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma$424,323
R01 · FY2021 · CA · contact PI
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma$424,323
R01 · FY2020 · CA · contact PI
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma$189,125
U54 · FY2020 · CA · contact PI
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma$5,000,000
U54 · FY2019 · CA · contact PI
Targeting the oncoprotein that drives FLC$3,725,015
U54 · FY2019 · CA · contact PI
What differences between the chimeric fusion oncoprotein DNAJB1-PRKACA and native kinase PRKACA lead to transformation in the childhood cancer, fibrolamellar hepatocellular carcinoma?$805,461
U54 · FY2019 · CA · contact PI
Admin Core$469,524
U54 · FY2019 · CA · contact PI
Single virions to study assembly of HIV-1$334,763
R01 · FY2019 · GM · contact PI
Single virions to study assembly of HIV-1$334,763
R01 · FY2018 · GM · contact PI
Single virions to study assembly of HIV-1$240,863
R01 · FY2018 · GM · contact PI
Single virions to study assembly of HIV-1$334,763
R01 · FY2017 · GM · contact PI
Cellular Pathogenesis of Fibrolamellar Hepatocellular Carcinoma$296,625
R56 · FY2017 · CA · contact PI
Single virions to study assembly of HIV-1$334,763
R01 · FY2016 · GM · contact PI
Cellular Pathogenesis of Fibrolamellar Hepatocellular Carcinoma$296,625
R56 · FY2016 · CA · contact PI
The Center for HIV RNA Studies (CRNA)$230,406
P50 · FY2016 · GM · contact PI
Single virions to study assembly of HIV-1$98,992
R01 · FY2016 · GM · contact PI
The Center for HIV RNA Studies (CRNA)$230,406
P50 · FY2015 · GM · contact PI
Analysis of force developed by a AAA ATPase$308,086
R01 · FY2014 · GM · contact PI
The Center for HIV RNA Studies (CRNA)$230,406
P50 · FY2014 · GM · contact PI
Biogenesis of HIV 1 in living cells$393,179
R01 · FY2013 · AI · contact PI
Analysis of force developed by a AAA ATPase$297,303
R01 · FY2013 · GM · contact PI
The Center for HIV RNA Studies (CRNA)$222,342
P50 · FY2013 · GM · contact PI
Biogenesis of HIV 1 in living cells$418,275
R01 · FY2012 · AI · contact PI
Selective fluorescent labeling of proteins in living cells$318,759
R01 · FY2012 · GM · contact PI
Analysis of force developed by a AAA ATPase$308,086
R01 · FY2012 · GM · contact PI
The Center for HIV RNA Studies (CRNA)$294,281
P50 · FY2012 · GM · contact PI
Biogenesis of HIV 1 in living cells$405,979
R01 · FY2011 · AI · contact PI
Analysis of force developed by a AAA ATPase$321,304
R01 · FY2011 · GM · contact PI
Selective fluorescent labeling of proteins in living cells$318,760
R01 · FY2011 · GM · contact PI
Biogenesis of HIV 1 in living cells$391,795
R01 · FY2010 · AI · contact PI
Selective fluorescent labeling of proteins in living cells$322,787
R01 · FY2010 · GM · contact PI
Selective fluorescent labeling of proteins in living cells$297,297
R01 · FY2010 · GM · contact PI
Selective fluorescent labeling of proteins in living cells$329,413
R01 · FY2009 · GM · contact PI
Imaging single proteins in vivo with quantum dots$125,219
P20 · FY2008 · GM · contact PI
Imaging single proteins in vivo with quantum dots$755,781
P20 · FY2007 · GM · contact PI
Imaging single proteins in vivo with quantum dots$756,118
P20 · FY2006 · GM · contact PI
Imaging single proteins in vivo with quantum dots$770,502
P20 · FY2005 · GM
Imaging single proteins in vivo with quantum dots$65,180
P20 · FY2005 · GM
Imaging single proteins in vivo with quantum dots (RMI)$722,733
P20 · FY2004 · GM
Large Scale Chemical Screen Against Pathogenic Bacteria$250,500
R21 · FY2003 · EB
OPSIN BIOGENESIS AND RETINITIS PIGMENTOSA$288,565
R01 · FY2002 · EY
Large Scale Chemical Screen Against Pathogenic Bacteria$250,500
R21 · FY2002 · EB
OPSIN BIOGENESIS AND RETINITIS PIGMENTOSA$280,158
R01 · FY2001 · EY
NON-ESTROGEN RECEPETOR TAMOXIFEN ACTIVITY$214,448
R01 · FY2001 · CA
OPSIN BIOGENESIS AND RETINITIS PIGMENTOSA$271,999
R01 · FY2000 · EY
NON-ESTROGEN RECEPETOR TAMOXIFEN ACTIVITY$207,889
R01 · FY2000 · CA